CHO transfected cells expressing the C57BL/6 allele of NKG2A and CD94
≥ 5.0 mg/ml
≤ 1.0 EU/mg as determined by the LAL method
≥95% monomer by analytical SEC
>95% by SDS Page
This monoclonal antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4 with no carrier protein, potassium, calcium or preservatives added.
Functional grade preclinical antibodies are manufactured in an animal free facility using only In vitro protein free cell culture techniques and are purified by a multi-step process including the use of protein A or G to assure extremely low levels of endotoxins, leachable protein A or aggregates.
Storage and Handling
Functional grade preclinical antibodies may be stored sterile as received at 2-8°C for up to one month. For longer term storage, aseptically aliquot in working volumes without diluting and store at -80°C. Avoid Repeated Freeze Thaw Cycles.
Country of Origin
Applications and Recommended Usage?
Quality Tested by Leinco
Flow Cytometry:For flow cytometric staining, the suggested use of this reagent is ≤0.5 µg per million cells in 100 µl volume. An appropriate secondary used would be a goat-anti-mouse IgG2b FITC or brighter fluorochrome when needed.
Other Applications Reported In Literature ?
Each investigator should determine their own optimal working dilution for specific applications. See directions on lot specific datasheets, as information may periodically change.
Clone 20D5 recognizes an epitope on the mouse NKG2A, NKG2C, and NKG2E isoforms of the CD94/NKG2 heterodimer. DBA/2J mice are CD94-deficient and do not express CD94/NKG2 receptors.
NKG2A/C/E is expressed on NK cells, NKT cells, and activated CD8 T cells.
NKG2A/C/E antibody, clone 20D5, recognizes the NKG2A, NKG2C, and NKG2E isoforms (also known as CD159a, CD159c,m CD159e, respectively) of the NKG2 receptor, belonging to the C-type lectin-like family. NKG2 receptors are expressed at the cell surface as a heterodimer with CD94 and recognize the non-classical class I MHC-1 molecules HLA-E in humans and Qa-1 in mice1-4. NKG2A/C/E are expressed on natural killer (NK) cells, NKT cells, and activated CD8 T cells5-6. Engagement of NKG2A/CD94 transduces an inhibitory signal, blocking NK and CD8 T cell cytotoxicity and promoting self-tolerance7. In contrast, NKG2C/CD94 and NKGE/CD94 are activating receptors8 and bind with lower affinity to HLA-E9. Cancer cells frequently overexpress HLA-E to protect against NK/CD8 T cell killing, and blocking NKG2 receptors in mice promotes anti-tumor immunity and may enhance the cytotoxic potential of other therapeutic antibodies10,11. The NKG2 receptor antibody monalizumab is currently in phase III clinical trials (INTERLINK-1) in combination with cetuximab in patients with recurrent or metastatic squamous cell carcinoma of the head and neck.
Inhibitory activity via ITIMs
References & Citations
1. Vance R.E., et al. (1998) J. Exp. Med. 188:1841–1848
2. Braud VM, et al. (1998) Nature. 391(6669):795-9
3. Vance RE, et al. (1999) J Exp Med. 190(12):1801-1812
4. Brooks AG, et al. (1997) J Exp Med. 185(4):795-800
5. Gunturi A, Berg RE, Forman J. (2004) Immunol Res. 30(1):29-34
6. Bertone S, et al. (1999) Eur J Immunol. 29(1):23-9
7. Le Dréan E, et al. (1998) Eur J Immunol. 28(1):264-76
8. Lanier LL, et al. (1998) Immunity. 8(6):693-701
9. Kaiser BK, et al. (2005) J Immunol. 174(5):2878-84
10. André P, Denis C, Soulas C, et al. (2018) Cell. 175(7):1731-1743.e13
11. van Montfoort N, Borst L, Korrer MJ, et al. (2018) Cell. 175(7):1744-1755.e15